The unit underwent an inspection from the United States Food and Drug Administration (US FDA) during 22 May-31 May and the inspection classification was determined by the agency as Voluntary Action Indicated (VAI).

C.C. Paarthipan, Chairman said, “This is the fourth US FDA audit at this site and we're pleased to receive the EIR with a satisfactory outcome. Our commitment to maintaining the highest levels of compliance at all our units remains steadfast. The receipt of EIR will help in receiving continued ANDA approvals for this unit, which is an important growth engine for us”.

Caplin Point Laboratories is engaged in the business of pharmaceuticals - producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.

The company's consolidated net profit jumped 21.7% to Rs 103.43 crore on 14.1% rise in net sales to Rs 395.32 crore in Q1 FY24 over Q1 FY23.

Shares of Caplin Point Laboratories declined 1.57% to Rs 1,078.80 on the BSE.